Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Chardan Capital Downgrades Vascular Biogenics to Neutral

Chardan Capital analyst Matthew Barcus downgrades Vascular Biogenics (NASDAQ:VBLT) from Buy to Neutral.
byBenzinga Newsdesk
July 21, 2022
1 minute read
Total
0
Shares
0
0
0
0
0
0

Chardan Capital analyst Matthew Barcus downgrades Vascular Biogenics (NASDAQ:VBLT) from Buy to Neutral.

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts
Read More

Beyond, Inc. Announces Partnership With X, To Deliver Custom Short And Long Form Content, Develop Customer Acquisition And Retention Strategies As Well As Spotlight The Companies’ Brands On Key Tent-Pole Events And Holidays

By Benzinga Newsdesk
March 27, 11:51 AM
Partnership includes short and long form lifestyle entertainment content on the companies' respective handles, targeted commerce campaigns as well as future shopping integration.Beyond, Inc. (NYSE:BYON), the parent

BYON